Anavex Life Sciences (AVXL) Income from Continuing Operations (2016 - 2025)
Anavex Life Sciences (AVXL) reported Income from Continuing Operations of 2555410000.0 for Q4 2025, down 2990.0% on a YoY basis from 88422577.37 in Q4 2024, and up 93.57% sequentially from 39726452000.0 in Q3 2025.
Anavex Life Sciences (AVXL) Income from Continuing Operations (2016 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 10 years of Income from Continuing Operations data on file, last reported at 2555410000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 2990.0% year-over-year to 2555410000.0; the trailing twelve-month figure through Dec 2025 stood at 42393274468.0 (down 36070.68% YoY), and the FY2025 full-year result was 39767016000.0, down 92377.13% from the prior year.
- Income from Continuing Operations rose to 2555410000.0 in Q4 2025, from 39726452000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 8182210.0 in Q1 2021 to a low of 39726452000.0 in Q3 2025.
- A 5-year average of 2132228877.5 and a median of 11979000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 33.53% in 2023 and slumped 338170.2% in 2025, its largest moves.
- Tracing AVXL's Income from Continuing Operations over 5 years: stood at 10882367.0 in 2021, then dropped by 19.2% to 12972000.0 in 2022, then surged by 33.53% to 8622000.0 in 2023, then plunged by 859.17% to 82699428.0 in 2024, then tumbled by 2990.0% to 2555410000.0 in 2025.
- Business Quant data shows AVXL's Income from Continuing Operations at 2555410000.0 in Q4 2025, 39726452000.0 in Q3 2025, and 60269270.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - | -2.56 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.56 Bn |
| Sep 30, 2025 | -39.73 Bn |
| Jun 30, 2025 | -60.27 Mn |
| Mar 31, 2025 | -51.14 Mn |
| Dec 31, 2024 | -82.70 Mn |
| Sep 30, 2024 | -11.74 Mn |
| Jun 30, 2024 | -12.21 Mn |
| Mar 31, 2024 | -10.55 Mn |
| Dec 31, 2023 | -8.62 Mn |
| Sep 30, 2023 | -10.15 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -13.11 Mn |
| Dec 31, 2022 | -12.97 Mn |
| Sep 30, 2022 | -14.29 Mn |
| Jun 30, 2022 | -12.37 Mn |
| Mar 31, 2022 | -10.44 Mn |
| Dec 31, 2021 | -10.88 Mn |
| Sep 30, 2021 | -11.59 Mn |
| Jun 30, 2021 | -10.22 Mn |
| Mar 31, 2021 | -8.18 Mn |